0R2B Stock Chart & Stats
$198.31
-$2.86(-1.44%)
At close: 4:00 PM EDT
$198.31
-$2.86(-1.44%)
Day’s Range― - ―
52-Week Range$159.95 - $244.50
Previous CloseN/A
Volume3.55K
Average Volume (3M)5.48K
Market Cap
$151.40B
Enterprise Value$162.35K
Total Cash (Recent Filing)$4.35B
Total Debt (Recent Filing)$26.56B
Price to Earnings (P/E)38.2
Beta1.06
Next Earnings
Oct 27, 2026EPS Estimate
1.92Next Dividend Ex-DateN/A
Dividend Yield0.67%
Share Statistics
EPS (TTM)5.65
Shares Outstanding702,986,100
10 Day Avg. Volume6,129
30 Day Avg. Volume5,482
Financial Highlights & Ratios
PEG Ratio-9.26
Price to Book (P/B)3.08
Price to Sales (P/S)6.59
P/FCF Ratio30.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$219.78Price Target Upside10.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)8.51
Revenue Forecast (FY)$26.31B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationDanaher’s installed-base model produces cash beyond accounting earnings, funding R&D, acquisitions and shareholder returns while reducing dependence on periodic instrument sales. High conversion indicates durable economics across research, diagnostics and bioprocessing workflows.
Recurring Installed-Base RevenueRecurring reagents, consumables, software and service revenue tied to mission-critical instruments can deepen customer retention and create lifecycle revenue. Once platforms are adopted in regulated workflows, switching costs and repeat usage support demand resilience.
Improving Core Growth And Portfolio ExpansionUnderlying demand is improving while portfolio additions broaden growth exposure: core ex-respiratory growth accelerated, EPS guidance rose, and Masimo plus StatLab add diagnostics scale and recurring revenue. This supports medium-term portfolio expansion.
Bears Say
Modest Revenue Growth And Lower ReturnsTTM revenue growth is only ~1.3% after softer 2023–2025 performance, while net margin and ROE remain below 2021–2022 peaks. This suggests recovery is gradual and leaves earnings more reliant on productivity and portfolio execution.
Bioprocessing Timing And Visibility RiskDelayed chromatography resin shipments and limited visibility into customer production schedules can create multi-quarter revenue volatility. Even with healthy orders, site-readiness and shipment timing may defer bioprocessing growth and reduce planning confidence.
Developed-Market And Academic Demand WeaknessSoftness in North America and Western Europe, alongside under-normal academic funding, can delay instrument purchases and research spending. Although academia is less than 5% of revenue, prolonged weakness may constrain recovery in research-oriented end markets.
Danaher News
0R2B FAQ
What was Danaher Corp.’s price range in the past 12 months?
Danaher Corp. lowest share price was $159.95 and its highest was $244.50 in the past 12 months.
What is Danaher Corp.’s market cap?
Danaher Corp.’s market cap is $151.40B.
When is Danaher Corp.’s upcoming earnings report date?
Danaher Corp.’s upcoming earnings report date is Oct 27, 2026 which is in 60 days.
How were Danaher Corp.’s earnings last quarter?
Danaher Corp. released its earnings results on Jul 21, 2026. The company reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.851 by $0.089.
Is Danaher Corp. overvalued?
According to Wall Street analysts Danaher Corp.’s price is currently Undervalued.
Does Danaher Corp. pay dividends?
Danaher Corp. pays a Quarterly dividend of $0.4 which represents an annual dividend yield of 0.67%. See more information on Danaher Corp. dividends here
What is Danaher Corp.’s EPS estimate?
Danaher Corp.’s EPS estimate is 1.92.
How many shares outstanding does Danaher Corp. have?
Danaher Corp. has 702,986,100 shares outstanding.
What happened to Danaher Corp.’s price movement after its last earnings report?
Danaher Corp. reported an EPS of $1.94 in its last earnings report, beating expectations of $1.851. Following the earnings report the stock price went down -12.013%.
Which hedge fund is a major shareholder of Danaher Corp.?
Currently, no hedge funds are holding shares in GB:0R2B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Danaher Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$219.78 (10.83% Upside)
$219.78 (10.83% Upside)
Blogger Sentiment
Bullish
GB:0R2B Sentiment 75%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $12.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.87%
12-Months-Change
Fundamentals
Return on Equity
0.67%
Trailing 12-Months
Asset Growth
13.17%
Trailing 12-Months
Company Description
Danaher Corp.
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.
0R2B Company Deck
0R2B Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive momentum: revenue and core growth accelerated sequentially (core ex-respiratory +4.5%), EPS grew ~8% and guidance was raised, cash generation was strong (Q2 FCF $1.3B, YTD conversion 124%), and life sciences and diagnostics showed solid performance with several product and M&A catalysts (Masimo closed early and is accretive; StatLab acquisition announced). Key challenges include bioprocessing shipment timing that pushed just over $100M into next year, respiratory-related headwinds (notably in Q3), modest margin pressure (down 20 bps), and continued softness in academic funding. On balance the positive operational execution, cash generation, guidance raise, and strategic M&A/repurchases outweigh the near-term timing and respiratory headwinds.View all GB:0R2B earnings summaries0R2B Revenue Breakdown
29.68% Biotechnology
29.85% Life Sciences
40.46% Diagnostics
0R2B Stock 12 Month Forecast
Average Price Target
$219.78
▲(10.83% Upside)